US OptionsDetailed Quotes

AMGN240719C327500

Watchlist

7.75
+3.10+66.67%

15min DelayTrading Jul 16 14:05 ET

8.70High6.73Low

Amgen Stock Discussion

Meltyy

Jun 17 22:06

$Amgen(AMGN.US)$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO

Meltyy

Jun 7 03:39

🚨 June PDUFAs

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...

ProperMicheleV

May 29 12:28

Down

I hate these days. I know it's investing & I'm long with my bets, but I have better, more exciting days when I don't see a lot of red. Sucks. And, I was terminated from my job in April & having a hard time getting unemployment. I was a 1099 contractor on that job & the department of labor doesn't know how to process my claim. This is making me low on hard cash & I'm going to have to sell a position or 2, and I DO NOT WANT TO DO THAT, especially with $Esperion Therapeutics (ESPR.US)$. I read...

life is a blessing

May 29 00:29

Esperion Therapeutics Is Now A Top Choice Takeover Target

$Esperion Therapeutics(ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...

Shaaaw

May 28 02:14

$Viking Therapeutics(VKTX.US)$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co(LLY.US)$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US)$ 50-100 Billion if not wrong
$Amgen(AMGN.US)$ 20+ Billion on no data yet

frankinglily: 在过去的18个月里 $礼来 (LLY.US)$ 的市值已从3,400亿美元上升到今天的大约7,700亿美元，必须有近3000亿至4000亿美元归因于 GLP-1，同意吗？如果接近真实，这只是表明其估值...

Meltyy

May 24 03:20

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...

Meltyy

May 20 21:57

🔔 FDA PDUFA Update…

📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...

AntiPerfect

May 5 01:24

$Amgen(AMGN.US)$ 🤔$450-$475? Friday?🤑🤑🤑All Money In

Kevin Travers

May 3 11:17

ColumnsFinally Friday, Finally May. Higher Unemployment? Investors say 'Buy Now' | Market Moovers

Morning mooers! It is Friday, May 3rd, and the market green after a jam-packed Q1 earnings week.
This time around, FOMC nonaction and low jobs numbers helped push equities in the green, or it migh just be because April is finally over. My name is Kevin Travers, here are stories moving the market:
MOOVERS
$Amgen (AMGN.US)$'s stock soared 12% toward biggest gain in 15 years, adding more than 220 points to the...

No comment yet